Jazz Pharmaceuticals Announces Promising Phase 3 Results for Ziihera in Treating HER2-Positive Gastroesophageal Adenocarcinoma
1. A Breakthrough in Cancer Treatment
On November 17, 2025, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) unveiled compelling results from the Phase 3 HERIZON-GEA-01 clinical trial, reinforcing the potential of Ziihera® (zanidatamab-hrii) as a leading anti-HER2 therapeutic agent. This study assessed Ziihera in combination with chemotherapy and the PD-1 inhibitor Tevimbra® (tislelizumab) as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA).
2. Significant Findings from HERIZON-GEA-01 Trial
The trial's primary endpoints—progression-free survival (PFS) and overall survival (OS)—bolstered Ziihera's position as a strong candidate for standard care in this challenging cancer landscape. Key findings include:
- Progression-Free Survival: Both Ziihera plus chemotherapy and Ziihera plus tislelizumab and chemotherapy exhibited highly significant improvements in PFS compared to the control arm, which utilized trastuzumab plus chemotherapy.
- Overall Survival: The combination of Ziihera with tislelizumab and chemotherapy yielded clinically meaningful and statistically significant enhancements in OS. Although Ziihera plus chemotherapy demonstrated a strong trend towards statistical significance in OS, full confirmation awaits further interim analyses expected in mid-2026.
- Subgroup Analysis: Notably, PFS and OS benefits were observed across both PD-L1 positive and PD-L1 negative subgroups, suggesting a broad applicability of Ziihera's efficacy.
- Secondary Endpoints: The trial also recorded improvements in objective response rate (ORR) and duration of response (DoR) for both Ziihera combination regimens, reinforcing the primary efficacy results.
3. Expert Commentary
Dr. Kohei Shitara, a principal investigator at the National Cancer Center Hospital East in Japan, commented on the implications of these results: "This is the first Phase 3 trial to demonstrate a benefit for a novel HER2-targeted therapy compared to trastuzumab as part of a combination regimen in HER2+ first-line GEA. The zanidatamab plus chemotherapy combination, with and without tislelizumab, has the potential to become the new standard of care."
Echoing this sentiment, Rob Iannone, M.D., M.S.C.E., Jazz's executive vice president and chief medical officer, expressed optimism regarding Ziihera's future: "We expect Ziihera to become the new standard of care anti-HER2 therapy for patients with HER2+ first-line metastatic GEA regardless of PD-L1 status."
4. Next Steps for Jazz Pharmaceuticals
Jazz Pharmaceuticals plans to engage with the FDA promptly, with intentions to file a supplemental Biologics License Application (sBLA) in the first half of 2026. This submission aims to position Ziihera as a first-line treatment option for HER2+ locally advanced or metastatic GEA in conjunction with standard chemotherapy regimens.
In addition, the company intends to present these significant findings at a major medical meeting in early 2026 and seeks publication in a peer-reviewed journal. Furthermore, Jazz aims to facilitate the adoption of Ziihera into the National Comprehensive Cancer Network® Guidelines (NCCN Guidelines®).
5. Broader Research Initiatives
Ziihera's development extends beyond GEA, with ongoing trials exploring its efficacy in various HER2-expressing cancers, including biliary tract cancer and metastatic breast cancer. The HERIZON-BTC-302 trial is currently evaluating Ziihera in combination with CisGem (cisplatin plus gemcitabine), while the EmpowHER-303 trial compares Ziihera against trastuzumab in patients with HER2-positive metastatic breast cancer.
6. Conclusion
The promising results from the HERIZON-GEA-01 trial signify a critical advancement in the treatment of HER2-positive gastroesophageal adenocarcinoma. As Jazz Pharmaceuticals moves forward with its regulatory submissions and further research, Ziihera stands poised to redefine therapeutic standards for patients battling this aggressive cancer type. With the potential for practice-changing outcomes, the oncology landscape may soon see a new beacon of hope for patients facing limited options.
